Clinical Trials on Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder

Total 1657 results

Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Lymphoma | Advanced Cancer | Refractory Solid Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University of Nebraska
M.D. Anderson Cancer Center

Terminated

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Advanced Solid Tumors | Relapsed/Refractory Lymphoma

United States
State Budgetary Healthcare Institution, National...

Unknown

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation (BeEAC-1)

Relapsed/Refractory Malignant Lymphomas

Russian Federation
University of Aarhus
Aarhus University Hospital

Completed

Early Detection of Epstein-Barr Virus Related Disease.

Epstein-Barr Virus Infections | Post-transplant Lymphoproliferative Disorder | Hemophagocytic Lymphohistiocytoses | Epstein-Barr Virus-Related Hodgkin Lymphoma | Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | Mononucleosis | Epstein-Barr Virus Related Malignancy | Epstein-Barr Viraemia | Hemophag...

Denmark
Allogene Therapeutics

Active, not recruiting

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)

Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Large B Cell Lymphoma

United States
Cedars-Sinai Medical Center

Completed

Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant

Lymphoma | Multiple Myeloma | Transplant-Related Disorder

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

Advanced Solid Tumors | Relapsed/Refractory Lymphoma

United States
Federal Research Institute of Pediatric Hematology...

Unknown

Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

Refractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia

Russian Federation
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Recruiting

HHV8 and Solid Organ Transplantation

Castleman Disease | Kaposi Sarcoma | Liver Transplant; Complications | Lung Transplant; Complications | Kidney Transplant; Complications | HHV8 | HHV8 Infection | HHV8-Related Malignant Neoplasm

Italy
The Lymphoma Academic Research Organisation

Active, not recruiting

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Refractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell Lymphoma

France
Lantern Pharma Inc.

Recruiting

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid Tumor | Relapsed or Refractory Lymphomas

United States
Cristiana Sessa

Completed

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (IOSI-LND-001)

B-cell Lymphoma Refractory

Switzerland
Reinhold Munker

Completed

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Refractory Lymphoma | Refractory Leukemia | Efficacy, Self | T-lymphoblastic Lymphoma | Safety | Relapsed Disease

China
University of Kansas Medical Center
Millennium Pharmaceuticals, Inc.

Completed

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

Autologous Transplant | Malignant Lymphoma, Stem Cell Type

United States
Stanford University
National Institutes of Health (NIH)

Completed

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin | Blood and Marrow Transplant (BMT) | Lymphomas: Non-Hodgkin

United States
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
Fondazione Italiana Linfomi ONLUS

Completed

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Relapsed/Refractory Hodgkin's Lymphoma

Italy
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Recruiting

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Relapsed or Refractory Mature Lymphoid Neoplasms

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase I/II Study of Avelumab in Pediatric Cancer Subjects

Lymphoma | Refractory or Relapsed Solid Tumors

Korea, Republic of, United States, Canada, Belgium, Denmark
Seoul National University Hospital
Seoul National University Bundang Hospital; SMG-SNU Boramae Medical Center

Completed

Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas (Bretuximab)

Relapsed or Refractory EBV-and CD30-positive Lymphomas

Korea, Republic of
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Recurrent Nervous System Lymphoma | Recurrent Primary Vitreoretinal DLBCL | Refractory Nervous System Lymphoma | Refractory Primary Vitreoretinal DLBCL

United States
Scripps Translational Science Institute
Cue Health

Active, not recruiting

ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

HIV Infections | Lymphoma | Leukemia | Cancer | Multiple Myeloma | Immunosuppression | Immunodeficiency | Transplant | Graft Versus Host Disease | Age-Related Immunodeficiency

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Novartis Pharmaceuticals

Completed

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (MACS1271)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple Myeloma

United States
Stanford University

Completed

Allo BMT in Advanced Leukemia or High Grade Lymphoma

Lymphoma, Non-Hodgkin | Leukemia | Blood and Marrow Transplant (BMT) | Lymphomas: Non-Hodgkin

United States
BeiGene

Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma

China
Chinese PLA General Hospital

Recruiting

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

China
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients (FIL_A-BEGEV)

Relapsed or Refractory Hodgkin's Lymphoma

Italy
National Cancer Center, Korea

Recruiting

Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Relapsed/Refractory Classical Hodgkin Lymphoma

Korea, Republic of
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma | Relapsed or Refractory Hodgkin Lymphoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (ORIENT-1)

Relapsed/Refractory Classical Hodgkin's Lymphoma

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

France, Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
Tayu Huaxia Biotech Medical Group Co., Ltd.

Recruiting

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Locally Advanced /Metastatic Solid Tumors | Relapsed or Refractory Lymphomas

China
Multinational Center for Quality of Life Research...

Unknown

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

Relapsed or Refractory Hodgkin's Lymphoma

Russian Federation
Xin Wang

Unknown

The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

Relapsed or Refractory B-cell Lymphomas

China
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
Children's Mercy Hospital Kansas City

Completed

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

Refractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric AML | Relapsed Pediatric ALL

United States

Clinical Trials on Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations